Merck & Co. signs a licensing agreement with the UN-backed Medicines Patent Pool that will allow more companies to manufacture generic versions of its experimental oral…
Merck & Co. signs a licensing agreement with the UN-backed Medicines Patent Pool that will allow more companies to manufacture generic versions of its experimental oral antiviral COVID-19 treatment molnupiravir with a royalty-free license that will apply to 105 low- and middle-income countries.
Herald Premium Archive
This report is for subscribers
Sign in or choose a plan to read this report and the complete Premium retrospective archive.
HealthMerck & Co. signs a licensing agreement with the UN-backed Medicines Patent Pool that will allow more companies to manufacture generic versions of its experimental oral…
View Premium plansBrowse free archive reportsMerck & Co. signs a licensing agreement with the UN-backed Medicines Patent Pool that will allow more companies to manufacture generic versions of its experimental oral antiviral COVID-19 treatment molnupiravir with a royalty-free license that will apply to 105 low- and middle-income countries.